Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Dexamethasone Isonicotinate→

Dexamethasone Isonicotinate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2265-64-7
Molecular formula
C28H32FNO6
Molecular weight
497.6 g/mol
Drug class
Dexamethasone estersynthetic glucocorticoid prodrug/formulation
Mechanism of action
Hydrolysed to dexamethasone, which activates glucocorticoid receptors and suppresses inflammatory cytokines, immune-cell migration and other inflammatory gene expression. Route and ester formulation determine systemic exposure and indication.
Indications / reported uses
  • Used in authorised systemic or local corticosteroid formulations for inflammatory, allergic and autoimmune conditions; precise indication depends on the specific dexamethasone isonicotinate product and route. Do not transfer all dexamethasone indications to every ester formulation.

Sources: NLM MeSH — Dexamethasone · PubMed — Dexamethasone isonicotinate formulation · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Dexamethasone Isonicotinate Environmental Risk Assessment (ERA) (the Dexamethasone Isonicotinate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.